<DOC>
	<DOCNO>NCT00860639</DOCNO>
	<brief_summary>The main objective study improve outcome young patient ( 18-60 year ) acute myeloid leukemia intermediate risk define cytogenetics . In population , absence bone marrow transplantation , event free survival ( EFS ) estimate 35 % three year follow-up . Adjunction gemtuzumab ozogamycin ( MYLOTARG® ) standard chemotherapy suppose increase EFS 50 % 3 year . To test hypothesis , Groupe Ouest Est d'Etude de Leucémies et Autres Maladies du Sang ( GOELAMS ) sponsor Nantes University Hospital lead randomize open phase III trial 29 French center .</brief_summary>
	<brief_title>Efficacy Gemtuzumab Ozogamycin Patients Presenting Acute Myeloid Leukemia ( AML ) With Intermediate Risk</brief_title>
	<detailed_description>Initial randomization complete upon receipt karyotype result determine administration gemtuzumab ozogamycin ( MYLOTARG ® ) combination chemotherapy induction course first intensive consolidation course . The induction course include : Daunorubicin 3 day ( 60mg/m² ) associate cytarabine ( 200mg/m² ) 7 day . The MYLOTARG ® administer accord randomization arm 4th day treatment slow intravenous infusion 2 hour dose 6 mg/m2 . Early bone marrow assessment perform D15 . In case blast excess ( &gt; 5 % ) , second course induction administer . The consolidation treatment depend age , molecular prognostic factor , donor availability : - Patients good molecular prognosis profile [ NPM1 + / FLT3 ITD - CEBPa mutate ] consolidate two course intensive chemotherapy comprise Mitoxanthrone intermediate dose Cytarabine without MYLOTARG ® accord initial randomization first course . - Patients young 51 year , eligible standard allogeneic transplantation sibling full match unrelated donor receive standard bone marrow transplantation begin 90 day induction . - Patients donor old 50 year , donor identify , receive two course intensive consolidation comprise Mitoxantrone intermediate-dose Cytarabine without Mylotarg ® 6 mg / m² first consolidation accord randomisation arm . - Patients age 51 60 year HLA identical donor ( sibling unrelated ) , receive non-myeloablative haematopoietic stem cell transplant ( HSCT ) second course consolidation . - For patient , autologous hematopoietic stem cell transplant ( HSCT ) perform 2nd course consolidation . Collection peripheral blood stem cell ( PBSCs ) perform first consolidation course second collection may consider second consolidation course case inadequate collection .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Adult patient de novo AML intermediate risk define cytogenetics criterion GOELAMS Group : Normal karyotype Karyotype abnormality , exclude favourable group [ ( 15 ; 17 ) , ( 8 ; 21 ) , inv ( 16 ) ] high risk group [ ( 5/5q , 7/7q , ( 9.22 ) , ( 6.9 ) , 11q23 anomaly exclude ( 9 ; 11 ) , abnormal 3q , complex karyotype ( &gt; 3 abnormality ) ] . Not previously treat AML . Patients age 18 60 year And 20 % blast cell bone marrow previously describe . And intermediate cytogenetics previously define And whose expression CD33 antigen blast define use standard method And WBC &lt; equal 100G/L . And receive either one treatment study And good performance status ( WHO score &lt; 3 ) life expectancy great one month . Affiliated Social Security Patients age 18 60 year OR AML : Not classifiable classification FrenchAmericanBritish ( FAB ) Type M3 Or blastic transformation myeloproliferative myelodysplastic syndrome previously diagnose Outside intermediate cytogenetic group previously define OR isolate extramedullary localization disease OR WBC &gt; 100G / L Patients know human immunodeficiency virus ( HIV ) infection human Tlymphotrophic virus 1 ( HTLV1 ) Patients SGOT/SGPT &gt; 5N Patients calculated creatinine clearance &lt; 50 mL/min Informed consent refusal Pregnant and/or lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>gemtuzumab ozogamycin</keyword>
</DOC>